Enzastaurin

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cutaneous T-Cell Lymphoma

Conditions

Cutaneous T-Cell Lymphoma

Trial Timeline

Sep 1, 2008 → Feb 1, 2010

NCT ID

NCT00744991

About Enzastaurin

Enzastaurin is a phase 2 stage product being developed by Eli Lilly for Cutaneous T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00744991. Target conditions include Cutaneous T-Cell Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01432951	Phase 1	Completed	Nov 1, 2011	Jan 5, 2018	Solid Tumor
NCT00744991	Phase 2	Completed	Sep 1, 2008	Feb 1, 2010	Cutaneous T-Cell Lymphoma
NCT00718419	Phase 2	Completed	Jul 1, 2008	Aug 1, 2012	Waldenstrom's Macroglobulinemia
NCT00542919	Phase 2	Completed	Nov 1, 2007	Feb 27, 2018	T-Cell Lymphoma
NCT00475644	Phase 2	Completed	May 1, 2007	Dec 1, 2014	Lymphoma, Follicular
NCT00452257	Phase 1	Completed	May 1, 2007	Sep 1, 2008	Leukemia, Lymphocytic
NCT00420381	Phase 2	Completed	Jan 1, 2007	Dec 1, 2014	Ovarian Cancer
NCT00428714	Phase 2	Completed	Jan 1, 2007	Jan 1, 2011	Prostate Cancer
NCT00309140	Phase 2	Completed	Mar 1, 2006	Jul 1, 2009	Neoplasms
NCT00088205	Phase 2	Completed	Mar 1, 2004	May 1, 2008	Mantle-Cell Lymphoma
NCT00190723	Phase 2	Completed	Oct 1, 2002	Dec 1, 2006	Malignant Glioma

Competing Products

20 competing products in Cutaneous T-Cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
ONTAK (denileukin difitox, DAB389IL-2)	Eisai	Approved	85
ONTAK	Eisai	Approved	85
E7777 9 mcg/kg	Eisai	Phase 3	77
ONTAK	Eisai	Approved	85
Mogamulizumab	Kyowa Kirin	Approved	85
Mogamulizumab + Brentuximab vedotin	Kyowa Kirin	Phase 1	33
Mogamulizumab	Kyowa Kirin	Phase 2	52
KW-0761 + Vorinostat	Kyowa Kirin	Phase 3	77
Clopidogrel + Ticagrelor	AstraZeneca	Approved	85
Pembrolizumab	Merck	Phase 2	52
Comparator: vorinostat	Merck	Pre-clinical	23
Pembrolizumab	Merck	Phase 2	52
TR701 FA	Merck	Phase 2	52
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Tulisokibart + Placebo	Merck	Phase 2	52
Aspirin + Ipilimumab + Pembrolizumab	Merck	Phase 2	52
Pembrolizumab + Mogamulizumab	Merck	Phase 2	52
TR-701 FA + Linezolid	Merck	Phase 3	77
Pimasertib + Dacarbazine	Merck	Phase 2	52

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved